By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Northwest Biotherapeutics, Inc. 

21720 23rd Drive SE, Suite 100

Bothell  Washington  98021  U.S.A.
Phone: 425-608-3000-or-877-606-9246-Toll-Free Fax: 425-608-3026




Cytogen Corporation  Development of ex vivo prostate cancer immunotherapy

Company News
Northwest Biotherapeutics (NWBO) Announces Completion Of DCVax®-Direct Phase I Trial Recruitment 7/16/2014 8:28:38 AM
Northwest Biotherapeutics (NWBO) Biotechnology Industry Organization (BIO) Reaffirms DCVAX®-Direct Clinical Trial Interim Data Announcements 6/20/2014 7:13:51 AM
Northwest Biotherapeutics (NWBO) Named To Two Russell Indexes 6/16/2014 7:12:49 AM
Northwest Biotherapeutics (NWBO) Release: DCVAX-Direct Trial Update Indicates Further Positive Responses; 3 Case Studies Show No Live Tumor Cells In Injected Tumors 6/11/2014 9:50:50 AM
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Phase 3 Trial Initiated In Germany 6/10/2014 10:00:35 AM
Northwest Biotherapeutics (NWBO) To Present At Jefferies and Co. 2014 Global Healthcare Conference 6/4/2014 9:42:30 AM
Northwest Biotherapeutics (NWBO) Release: Early Positive Responses Seen In Over 50% Of Dcvax®-Direct Patients To Date 5/27/2014 9:53:29 AM
Northwest Biotherapeutics (NWBO) Announces First Data From Ongoing Dcvax-Direct Trial 5/15/2014 12:28:20 PM
Presentation On Northwest Biotherapeutics (NWBO)'s Dcvax-Direct Trial Announced For American Society of Clinical Oncology Annual Meeting 4/22/2014 6:32:06 AM
Northwest Biotherapeutics (NWBO) Scrounges Up $32 Million 4/10/2014 6:37:52 AM